Omniblend Innovation Pty Ltd

Starpharma Pty Limited

Immuron Limited

Daratech Proprietary Limited

Gottfried Lichti

Christopher Walter Lichti

Brian Devlin Kelly

Guy Yeoman Krippner

Benjamin James Boyd

Pasquale Razzino

Scott Andrew Henderson

Phillip Martin Rendle

Lisa Michelle Kaminskas

Christopher John Hamilton Porter

Charlotte Claire Williams

Angela Michelle Scheppokat

Peter Richard Wynter Best

Ben William Greatrex

Janena Frances Best

Roy Michael Robins-Browne

Grant Thomas Rawlin

Susanne Pallich

Alexander Serban

Jin Ling Chen

William Roy Jackson

Daryl K Wood

Paul A Horne

Janine J Kibblewhite

Darren J Park

Anthony G Flynn

Christopher John Porter

Peter Richard Best

A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or IGT the drink comprising: at least one water soluble or water dispersible material selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml per serving, and fenugreek fibre in an amount in the range of from 1 g to 15 g.

Composition and method for control of post-prandial glucose

A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising:

Composition and method for management of diabetes or pre-diabetes

A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.

The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.

Composition and method for the treatment and prevention of enteric bacterial infections

The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

Macromolecular compounds having controlled stoichiometry

Controlled release composition of biocide in an aqueous dispersion of

Growing community of inventors

Essendon, Australia

Gottfried Lichti